Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use

Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart failure (HF). In the ensuing 20 years, this distinctive inodilator, which enhances cardiac...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Cardiovasc Pharmacol
Päätekijät: Papp, Zoltán, Agostoni, Piergiuseppe, Alvarez, Julian, Bettex, Dominique, Bouchez, Stefan, Brito, Dulce, Černý, Vladimir, Comin-Colet, Josep, Crespo-Leiro, Marisa G., Delgado, Juan F., Édes, István, Eremenko, Alexander A., Farmakis, Dimitrios, Fedele, Francesco, Fonseca, Cândida, Fruhwald, Sonja, Girardis, Massimo, Guarracino, Fabio, Harjola, Veli-Pekka, Heringlake, Matthias, Herpain, Antoine, Heunks, Leo M. A., Husebye, Tryggve, Ivancan, Višnja, Karason, Kristjan, Kaul, Sundeep, Kivikko, Matti, Kubica, Janek, Masip, Josep, Matskeplishvili, Simon, Mebazaa, Alexandre, Nieminen, Markku S., Oliva, Fabrizio, Papp, Julius G., Parissis, John, Parkhomenko, Alexander, Põder, Pentti, Pölzl, Gerhard, Reinecke, Alexander, Ricksten, Sven-Erik, Riha, Hynek, Rudiger, Alain, Sarapohja, Toni, Schwinger, Robert H. G., Toller, Wolfgang, Tritapepe, Luigi, Tschöpe, Carsten, Wikström, Gerhard, von Lewinski, Dirk, Vrtovec, Bojan, Pollesello, Piero
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Journal of Cardiovascular Pharmacology 2020
Aiheet:
Perspectives
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7340234/
https://ncbi.nlm.nih.gov/pubmed/32639325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FJC.0000000000000859
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia